Harmony Biosciences (HRMY) Announces FDA Grants Priority Review for Application For Wakix (Pitolisant) In Pediatric Narcolepsy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. TSLA

Go back to Harmony Biosciences (HRMY) Announces FDA Grants Priority Review for Application For Wakix (Pitolisant) In Pediatric Narcolepsy

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $34 at Raymond James

February 22, 2024 12:00 PM EST

Raymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $34.00 (from $27.00) while maintaining a Outperform rating.

The analyst comments "Last month, HRMY preannounced 4Q Wakix sales and provided preliminary FY24 guidance that came in-line w/... More